How should I take IDHIFA?
IDHIFA is an oral medication that you can take at home
- Take IDHIFA exactly as your healthcare provider tells you to
- Take IDHIFA 1 time a day at the same time each day
- Swallow IDHIFA tablets whole with 8 ounces (1 cup) of water. Do not chew or split the tablet
- IDHIFA can be taken with or without food
- If you miss a dose of IDHIFA or vomit after taking a dose of IDHIFA, take the dose of IDHIFA as soon as possible on the same day. Then take your next dose the next day at your regularly scheduled time. Do not take 2 doses at the same time to make up for the missed dose
- Your healthcare provider should do blood tests to check your blood counts before you start IDHIFA treatment and at a minimum of every 2 weeks for at least the first 3 months during treatment to check for side effects
How long should I take IDHIFA?
- In the clinical trial, half of the 214 patients evaluated for safety took IDHIFA for more than 4.3 months, while half took it for less than that (range of 0.3 months to 23.6 months)
- In patients evaluated for efficacy and for whom IDHIFA worked (46 out of 199) the amount of time it took to see a response varied:
- Half of patients saw their first response after taking IDHIFA for 1.9 months (range of 0.5 months to 7.5 months), while for half it took longer
- Half of patients saw their best response after taking IDHIFA for 3.7 months (range of 0.6 months to 11.2 months), while for half it took longer
- Your doctor will decide how long you will take IDHIFA, so be sure to follow his or her instructions about treatment schedule and dose
How should I store IDHIFA?
- Store IDHIFA at temperatures of 68°F to 77°F (20°C to 25°C)
- Keep IDHIFA in the original container
- Keep the container tightly closed with desiccant canister (drying agent) inside to protect the tablets from moisture
Keep IDHIFA and all medicines out of reach of children.
Keep IDHIFA and all medicines out of reach of children.
General information about the safe and effective use of IDHIFA
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take IDHIFA for conditions for which it was not prescribed. Do not give IDHIFA to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IDHIFA that is written for health professionals.
Keep IDHIFA in the bottle it was prescribed in. Do not transfer IDHIFA to a pill sorter or other container
IDHIFA is availble in 2 tablet strengths:
100 mg
50 mg
What are the possible benefits of IDHIFA?
A clinical trial was done to determine the effectiveness and safety of IDHIFA in patients with relapsed or refractory AML with an IDH2 mutation. To study the effectiveness of IDHIFA, 199 patients were started on the 100-mg oral dose of IDHIFA every day until disease progression or unacceptable toxicity. Dose reductions were allowed to manage side effects.
IDHIFA helped patients achieve different levels of response.
Nearly
1 in 4 patients
(46 out of 199, or 23%)
responded to IDHIFA treatment
Achieving a “response” means that IDHIFA helped patients achieve a complete remission (CR) or complete remission with partial hematologic recovery (CRh). A CR occurs when a patient’s blood counts and bone marrow return to normal. A CRh means that no signs of the cancer were seen, but certain blood counts did not completely return to normal.
Achieved A CR
Half of patients who achieved a CR saw the benefit of IDHIFA last for more than 8.2 months, while half saw the benefit last for less than that.
Achieved A CRh
Half of patients who achieved a CRh saw the benefit of IDHIFA last for more than 9.6 months, while half saw the benefit last for less than that.
IDHIFA helped reduce the need for red blood cell or platelet transfusions.
More than
1 in 3 patients
(53 out of 157, or 34%)
became transfusion free.
This means that patients who needed red blood cell and/or platelet transfusions when the clinical trial began became transfusion free for a period of 8 weeks or more.
32 out of 42
patients (76%) remained
transfusion free.
This means that patients who did not need red blood cell and/or platelet transfusions when the clinical trial began remained transfusion free for a period of 8 weeks or more.
What are the possible side effects of IDHIFA?
To study the safety of IDHIFA, 214 patients with relapsed or refractory AML with an IDH2 mutation were assigned to receive the 100-mg oral dose of IDHIFA every day and were monitored for the appearance of side effects. You may experience side effects while taking IDHIFA. In the clinical trial, 92 out of 214 patients (43%) had their dose of IDHIFA interrupted, 10 out of 214 patients (5%) had their dose reduced, and 36 out of 214 patients (17%) had their dose discontinued due to side effects.IDHIFA may cause serious side effects, including:
-
Differentiation Syndrome. Differentiation syndrome is a condition that affects your blood cells which may be life-threatening or lead to death if not treated. Differentiation syndrome has happened within 10 days and up to 5 months after starting IDHIFA. Call your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following symptoms of differentiation syndrome while taking IDHIFA:
- Fever
- Cough
- Shortness of breath
- Swelling of arms and legs
- Swelling around neck, groin, or underarm area
- Fast weight gain (greater than 10 points within a week)
- Bone pain
The most common side effects of IDHIFA include:
- Nausea
- Vomiting
- Diarrhea
- Jaundice
- Decreased appetite
- Your healthcare provider will monitor you for side effects during treatment and may tell you to stop taking IDHIFA if you develop certain side effects
- Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088
To learn more about serious side effects and how they may affect you, speak with your healthcare team or refer to the Medication Guide.
Access downloadable PDFs and find additional information and tools for your treatment and disease.
VISIT OUR RESOURCES SECTION
